Adaptimmune Therapeutics PLC — Director's Dealing 2024

Jun 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2024-06-18

Reporting Person: Piccina Cintia (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-18	American Depositary Shares representing Ordinary Shares	S	24531	$0.9300	Disposed	38293	Direct

Footnotes

F1: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately one third of an RSU-style share option covering ordinary shares of the Issuer granted on March 18, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2: The price reported in Column 4 is the sale price per ADS.

F3: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,359 ADSs and RSU-style options and other options covering an aggregate of 6,968,400 ordinary shares of the Issuer.